Roche taps Janus for autoimmune R&D; Adaptive Bio gets into biotech R&D;

@FierceBiotech: Reborn Akari grabs $75M in financing for another Soliris rival. Article | Follow @FierceBiotech

@JohnCFierce: I'm sure the FDA feels ever so much better now that Addyi is in Valeant's hands. Oh yeah. | Follow @JohnCFierce

@DamianFierce: Turing has a new Form D reflecting that $90M claim but now including warrants and a loan. SEC filing | Follow @DamianFierce

> Roche ($RHHBY) has reached out to Janus Biotherapeutics to collaborate on a small-molecule treatment for autoimmune disease. More

> Gene sequencing outfit Adaptive Biotechnologies is getting into drug development, launching a new subsidiary called Adaptive Therapeutics to advance some cell therapies for cancer. Item

> Applied Genetic Technologies ($AGTC) closed its deal with Biogen ($BIIB), worth up to $1 billion in total, and saw its share price rise as much as 22%. News

Medical Device News

@FierceMedDev: BioDelivery snags new FDA approval for Onsolis after ditching Meda partnership. FierceDrugDelivery story | Follow @FierceMedDev

@VarunSaxena2: Edge files for up to $115M IPO to support locally delivered med for brain aneurysms. ICYMI from FierceDrugDelivery | Follow @VarunSaxena2

@EmilyWFierce: $ILMN CEO Flatley opens up about Helix and "app store" for human genomes. MIT Technology Review article | Follow @EmilyWFierce

> LDR raises $86.5M to back ongoing launch of cervical disc replacement device. More

> Boston Sci earns FDA approval of Innova stent to treat peripheral artery disease. Article

Pharma News

@FiercePharma: Horizon puts forth its slate of new Depomed directors. Story | Follow @FiercePharma

@EricPFierce: FDA warning letter castigates three Mylan sterile drug plants in India. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: In case you missed my foray into Google Forms, we're doing a survey on the next M&A move from $AGN. More | Follow @CarlyHFierce

> In a first for diabetes, Lilly and Boehringer's Jardiance prevents heart attacks, strokes in trial. Story

> Valeant sizes up women's health with $1B deal for Sprout and its libido drug. Article

Vaccines News

> Pfenex enters anthrax vaccines realm with $143.5M BARDA contract. News

> NIAID funds Soligenix with $2.7M in ricin vaccine effort. Report

> Team outlines potential target for aggressive breast cancer vaccine. Item

> WHO: Vaccine hesitancy is a mounting challenge for immunization programs. More

> Inovio's MERS vaccine shows 100% protection in mice, camels, monkeys. Article

CRO News

> Evotec's hybrid R&D model keeps revenue rolling. More

> U.K. CRO conglomerate bags another testing outfit with eyes on toxicology. Story

> Actelion taps DKSH to break into Asia. Item

> WuXi watches profits slip on its way to going private. Article

Pharma Manufacturing News

> Aurobindo lays out plans for 3 new plants. Item

> Mylan expands recalls from plants spanked in FDA warning letter. Article

> Merck recalls 276,000 bottles of cancer med that could pose risk to children. News

> Indonesia's Kimia to build $71M plant to make herbal meds. Story

> Union posts email exchange with Merck CEO over plant dangers from job cuts. Article

Pharma Asia News

> SK Chemicals ready to sell home-grown influenza vaccine as season gets underway. Report

> Mylan sees three Indian plants under FDA scanner on quality. Story

> Australia's Benitec prices Nasdaq IPO at $9.21 a share. Article

> Singapore's Asian American Medical eyes oncology expansion in southern China. More

> Australia's TGA registers Hospira's Inflectra. Item

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Months after approving a COVID-19 shot based on early data, Russia is reporting data from nearly 19,000 people showing it is more than 90% effective.

Early-stage biotech Elevian has raised $15 million as it looks to target multiple age-related diseases.

A month after seeing a "robust immune response" from a clutch of RSV vaccine hopefuls, GlaxoSmithKline is kicking off a key late-stage test.